CLAIMS:

1. A composition for stimulating hair growth comprising hyaluronic acid in a concentration of greater than 250 mcg/mL.

2. The composition of claim 1, wherein the hyaluronic acid has an average molecular weight in a range of about 4,000 Da to 10,000 Da.

3. The composition of claim 1 or 2, wherein the hyaluronic acid has an average molecular weight in a range of about 20 KDa to 1350 KDa.

4. The composition of any one of claims 1 to 3, wherein the hyaluronic acid is cross-linked.

5. The composition of any one of claims 1 to 4, wherein the hyaluronic acid has a cross-link density of about 20% or greater.

6. The composition of any one of claims 1 to 5, wherein the hyaluronic acid is present in a concentration of 250 mcg/mL to about 1000 mcg/mL.

7. Use of hyaluronic acid in the manufacture of a composition for treating hair loss in a patient in need thereof, wherein the composition is to be administered to the skin of the patient, and wherein the composition comprises hyaluronic acid in a concentration of greater than 250 mcg/mL.

8. The use of claim 7, wherein the composition is to be injected into a dermal layer of the skin.

9. The use of claim 7 or 8, wherein the composition is to be injected about 400 microns to about 2mm deep into the skin.

10. The use of any one of claims 7 to 9, wherein the composition is to be administered in a plurality of injections in an amount of about 400 injections/cm^2 skin to about 650 injections/cm^2 skin.

11. The use of any one of claims 7 to 10, wherein the composition further comprises a CD44-binding ligand.

12. The use of claim 11, wherein the CD44-binding ligand is osteopontin.

13. The use of any one of claims 7 to 12, wherein the composition is to be injected via a needle.

14. The use of claim 13, wherein the needle is a microneedle.

15. The composition of any one of claims 1 to 6, wherein the composition further comprises a CD44-binding ligand.

16. The composition of claim 15, wherein the CD44-binding ligand is osteopontin.

17. The composition of any one of claims 1 to 6, 15 and 16, for use in therapy.